Literature DB >> 17495418

Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrate.

Koichi Nakamura1, Akiko Watanabe, Noriko Okudaira, Osamu Okazaki, Kenichi Sudo.   

Abstract

An advantage of using LC-MS(/MS) for in vitro CYP inhibition screening is that it does not require extensive sample preparation and chromatographic separation. Attention must be paid, however, to ion suppression effects on analytes caused by the test compound as well as endogenous compounds. In this study, we have shown the ion suppression of 1'-hydroxymidazolam (analyte) and dextrorphan (IS) by erythromycin, as an example, which may cause over- or underestimation of CYP3A4 inhibition. To avoid this kind of effect, we proposed to use a stable isotope-labeled substrate and determine labeled metabolites by using unlabeled authentic compounds of each metabolite. We showed that CYP3A4 activity was determined with high accuracy and precision by using stable isotope-labeled midazolam even in the presence of an ion suppressor at high concentrations in the samples. This method is useful not only for the CYP inhibition screening but also for testing drug candidates to predict changes in metabolite formation by the possible co-administered drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495418     DOI: 10.2133/dmpk.22.113

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  2 in total

1.  Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Authors:  Sara K Quinney; Srikar R Malireddy; Raj Vuppalanchi; Mitchell A Hamman; Naga Chalasani; J Christopher Gorski; Stephen D Hall
Journal:  Eur J Clin Pharmacol       Date:  2012-07-10       Impact factor: 2.953

2.  Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.

Authors:  Nicolas Hohmann; Franziska Kocheise; Alexandra Carls; Jürgen Burhenne; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.